revealed that hepatocellular carcinoma patients with lower FAM134B expression was association with overall survival (p = 0.026), relapse-free survival(p = 0.0029), progression-free survival(p = 0.0089) and disease-specific survival(p = 0.015) (Fig. 2A). This evidence concerns the gene RETREG1 and hepatocellular carcinoma.